Selected research
Industry Research
Hepatic Encephalopathy Drug Industry Research Report 2026
Market perspective
The global Hepatic Encephalopathy Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Hepatic Encephalopathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Hepatic Encephalopathy Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Hepatic Encephalopathy Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Hepatic Encephalopathy Drug include Umecrine Cognition AB, Spherium Biomed S.L., Rebiotix Inc., Ocera Therapeutics, Inc., KannaLife Sciences, Inc., Horizon Pharma Plc, Cosmo Pharmaceuticals S.p.A and Alfa Wassermann S.p.A, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Hepatic Encephalopathy Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hepatic Encephalopathy Drug Market by Company
Umecrine Cognition AB
Spherium Biomed S.L.
Rebiotix Inc.
Ocera Therapeutics, Inc.
KannaLife Sciences, Inc.
Horizon Pharma Plc
Cosmo Pharmaceuticals S.p.A
Alfa Wassermann S.p.A
Hepatic Encephalopathy Drug Segment by Type
GR-3027
KLS-13019
RBX-2660
SYNB-1020
Others
Hepatic Encephalopathy Drug Segment by Application
Clinic
Hospital
Others
Hepatic Encephalopathy Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatic Encephalopathy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatic Encephalopathy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatic Encephalopathy Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Hepatic Encephalopathy Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Hepatic Encephalopathy Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Hepatic Encephalopathy Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- GR-3027
- KLS-13019
- RBX-2660
- SYNB-1020
- Others
Applications
- Clinic
- Hospital
- Others
Companies covered
- Umecrine Cognition AB
- Spherium Biomed S.L.
- Rebiotix Inc.
- Ocera Therapeutics, Inc.
- KannaLife Sciences, Inc.
- Horizon Pharma Plc
- Cosmo Pharmaceuticals S.p.A
- Alfa Wassermann S.p.A
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Hepatic Encephalopathy Drug Market Size (2021-2032)
- 2.2.2 Global Hepatic Encephalopathy Drug Sales (2021-2032)
- 2.2.3 Global Hepatic Encephalopathy Drug Market Average Price (2021-2032)
- 2.3 Hepatic Encephalopathy Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 GR-3027
- 2.3.3 KLS-13019
- 2.3.4 RBX-2660
- 2.3.5 SYNB-1020
- 2.3.6 Others
- 2.4 Hepatic Encephalopathy Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Hepatic Encephalopathy Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Hepatic Encephalopathy Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Hepatic Encephalopathy Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Hepatic Encephalopathy Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Hepatic Encephalopathy Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Hepatic Encephalopathy Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Hepatic Encephalopathy Drug, Product Type & Application
- 3.8 Global Manufacturers of Hepatic Encephalopathy Drug, Established Date
- 3.9 Global Hepatic Encephalopathy Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Umecrine Cognition AB
- 4.1.1 Umecrine Cognition AB Company Information
- 4.1.2 Umecrine Cognition AB Business Overview
- 4.1.3 Umecrine Cognition AB Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Umecrine Cognition AB Hepatic Encephalopathy Drug Product Portfolio
- 4.1.5 Umecrine Cognition AB Recent Developments
- 4.2 Spherium Biomed S.L.
- 4.2.1 Spherium Biomed S.L. Company Information
- 4.2.2 Spherium Biomed S.L. Business Overview
- 4.2.3 Spherium Biomed S.L. Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Spherium Biomed S.L. Hepatic Encephalopathy Drug Product Portfolio
- 4.2.5 Spherium Biomed S.L. Recent Developments
- 4.3 Rebiotix Inc.
- 4.3.1 Rebiotix Inc. Company Information
- 4.3.2 Rebiotix Inc. Business Overview
- 4.3.3 Rebiotix Inc. Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Rebiotix Inc. Hepatic Encephalopathy Drug Product Portfolio
- 4.3.5 Rebiotix Inc. Recent Developments
- 4.4 Ocera Therapeutics, Inc.
- 4.4.1 Ocera Therapeutics, Inc. Company Information
- 4.4.2 Ocera Therapeutics, Inc. Business Overview
- 4.4.3 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Product Portfolio
- 4.4.5 Ocera Therapeutics, Inc. Recent Developments
- 4.5 KannaLife Sciences, Inc.
- 4.5.1 KannaLife Sciences, Inc. Company Information
- 4.5.2 KannaLife Sciences, Inc. Business Overview
- 4.5.3 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Product Portfolio
- 4.5.5 KannaLife Sciences, Inc. Recent Developments
- 4.6 Horizon Pharma Plc
- 4.6.1 Horizon Pharma Plc Company Information
- 4.6.2 Horizon Pharma Plc Business Overview
- 4.6.3 Horizon Pharma Plc Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Horizon Pharma Plc Hepatic Encephalopathy Drug Product Portfolio
- 4.6.5 Horizon Pharma Plc Recent Developments
- 4.7 Cosmo Pharmaceuticals S.p.A
- 4.7.1 Cosmo Pharmaceuticals S.p.A Company Information
- 4.7.2 Cosmo Pharmaceuticals S.p.A Business Overview
- 4.7.3 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Product Portfolio
- 4.7.5 Cosmo Pharmaceuticals S.p.A Recent Developments
- 4.8 Alfa Wassermann S.p.A
- 4.8.1 Alfa Wassermann S.p.A Company Information
- 4.8.2 Alfa Wassermann S.p.A Business Overview
- 4.8.3 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Product Portfolio
- 4.8.5 Alfa Wassermann S.p.A Recent Developments
5 Global Hepatic Encephalopathy Drug Market Scenario by Region
- 5.1 Global Hepatic Encephalopathy Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Hepatic Encephalopathy Drug Sales by Region: 2021-2032
- 5.2.1 Global Hepatic Encephalopathy Drug Sales by Region: 2021-2026
- 5.2.2 Global Hepatic Encephalopathy Drug Sales by Region: 2027-2032
- 5.3 Global Hepatic Encephalopathy Drug Revenue by Region: 2021-2032
- 5.3.1 Global Hepatic Encephalopathy Drug Revenue by Region: 2021-2026
- 5.3.2 Global Hepatic Encephalopathy Drug Revenue by Region: 2027-2032
- 5.4 North America Hepatic Encephalopathy Drug Market Facts & Figures by Country
- 5.4.1 North America Hepatic Encephalopathy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Hepatic Encephalopathy Drug Sales by Country (2021-2032)
- 5.4.3 North America Hepatic Encephalopathy Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Hepatic Encephalopathy Drug Market Facts & Figures by Country
- 5.5.1 Europe Hepatic Encephalopathy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Hepatic Encephalopathy Drug Sales by Country (2021-2032)
- 5.5.3 Europe Hepatic Encephalopathy Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Hepatic Encephalopathy Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Hepatic Encephalopathy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Hepatic Encephalopathy Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Hepatic Encephalopathy Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Hepatic Encephalopathy Drug Market Facts & Figures by Country
- 5.7.1 South America Hepatic Encephalopathy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Hepatic Encephalopathy Drug Sales by Country (2021-2032)
- 5.7.3 South America Hepatic Encephalopathy Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Hepatic Encephalopathy Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Hepatic Encephalopathy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Hepatic Encephalopathy Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Hepatic Encephalopathy Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Hepatic Encephalopathy Drug Sales by Type (2021-2032)
- 6.1.1 Global Hepatic Encephalopathy Drug Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Hepatic Encephalopathy Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Hepatic Encephalopathy Drug Revenue by Type (2021-2032)
- 6.2.1 Global Hepatic Encephalopathy Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Hepatic Encephalopathy Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Hepatic Encephalopathy Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Hepatic Encephalopathy Drug Sales by Application (2021-2032)
- 7.1.1 Global Hepatic Encephalopathy Drug Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Hepatic Encephalopathy Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Hepatic Encephalopathy Drug Revenue by Application (2021-2032)
- 7.2.1 Global Hepatic Encephalopathy Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Hepatic Encephalopathy Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Hepatic Encephalopathy Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Hepatic Encephalopathy Drug Value Chain Analysis
- 8.1.1 Hepatic Encephalopathy Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Hepatic Encephalopathy Drug Production Mode & Process
- 8.2 Hepatic Encephalopathy Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Hepatic Encephalopathy Drug Distributors
- 8.2.3 Hepatic Encephalopathy Drug Customers
9 Global Hepatic Encephalopathy Drug Analyzing Market Dynamics
- 9.1 Hepatic Encephalopathy Drug Industry Trends
- 9.2 Hepatic Encephalopathy Drug Industry Drivers
- 9.3 Hepatic Encephalopathy Drug Industry Opportunities and Challenges
- 9.4 Hepatic Encephalopathy Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst